Nisha Gopal, PhD, is Co-Founder and Chief Scientific Officer at AbInitio Bio, an AI-powered biomanufacturing intelligence platform helping pharma and biotech teams accelerate drug development from candidate to commercial scale.

Nisha earned her B.S. in Biochemistry from the University of Michigan, completed a Fulbright-funded Master's in Biochemistry at the University of Pierre and Marie Curie in Paris, and earned her PhD in Structural Biology at Stanford University.

Nisha brings deep expertise in biochemistry, neuroscience, and structural biology, with research experience spanning infectious disease diagnostics and CRISPR-based detection assays at the Broad Institute of MIT and Harvard.

AbInitio Bio was accepted into Y Combinator's P26 batch, selected for MIT's R2E program for translating biomedical research into scalable ventures, and backed by Fifty Years venture fund through its 5050 program.

AbInitio's flagship model, Echo, predicts biomanufacturing outcomes more accurately than standard models, compressing process decisions that once took 6 to 18 months into hours for pharma and CDMO partners.